Nebulizer Market Size, Share & Trends Analysis Report By Type (Jet, Mesh, Ultrasonic), By End-use (Hospitals & Clinics, Emergency Centers & Home Healthcare), And Segment Forecasts, 2019 - 2026

Industry Insights

The global nebulizer market size was estimated at USD 870.1 million in 2018 and is anticipated to grow at a double digit CAGR of 6.5% over the forecast period. The high growth is attributed to the rising incidence rate of chronic respiratory diseases, increasing demand for home healthcare devices, and rising geriatric population. As per WHO, in 2017, primary cause of Chronic Obstructive Pulmonary Disease (COPD) in the U.S., was tobacco smoking. Thus, increase in number of smokers and environmental pollution is anticipated to increase the demand for nebulizers.

In addition, as per WHO, in 2017, there were around 3.17 million deaths worldwide due to COPD. However, initiatives such as the “Global Alliance against Chronic Respiratory Diseases” are likely to improve diagnosis and treatment rates of respiratory disorders, which may in turn boost the market for nebulizers.

The market for nebulizer and respiratory devices is quite mature with jet dominating the market due to the low cost. Hence, other nebulization devices are expected to experience high competition. Furthermore, it is a challenge for new technology or device to gain momentum in mature markets, particularly with the intricacies of different reimbursement and national regulatory systems that need to be followed for both drugs as well as devices.

Type Insights

Jet nebulizers are expected to account for the largest share in the global nebulizer market over the forecast period owing to the low cost of the devices. The mesh nebulizers segment is expected to witness lucrative market growth over the forecast period due to the technological advanced compact size devices and minimized drug loss thereby improving the effectiveness of the devices.

The market for mesh nebulizers is expected to grow further, majorly due to increased patient acceptance, quick treatment, portability, and convenience. Furthermore, increasing commercial acceptance of mesh nebulizers due to accurate drug delivery to the lung and lower residual volumes also aid in market penetration.

Ultrasonic nebulizers segment is anticipated to have steady growth owing to wider range of benefits such as increased portability, low drug delivery time, low noise generation during operative procedures, and high efficiency as a consequence of incorporation of high frequency wave oscillators. Other benefits associated with these devices include reduced size of drug droplets that lead to increased exposure of drugs to lungs, thereby inducing inclination of physicians toward ultrasonic nebulizers. Various products under this segment offered by the key players are Omron Corporation’s NE-U780 for clinical treatment of asthma, cystic fibrosis, & COPD and Briggs Healthcare’s NebPak Ultrasonic Nebulizer.

End Use Insights

Hospitals are expected to account for the largest share in the global nebulizer market over the forecast period owing to the favorable reimbursement policies and larger patient footfall. Furthermore, emergency centers are expected to witness lucrative growth owing to the increasing cases of sudden asthmatic attacks. According to WHO, 2017, increasing pollution, smoke and tobacco consumption have increased the rate of sudden asthmatic attacks worldwide.

Home healthcare devices have been gaining popularity and market share in recent years. Miniaturization of products and technological advancements are boosting the adoption of home healthcare devices. Furthermore, growing geriatric population, high incidence of target diseases, and growing need to curb healthcare expenditure are expected to be some of the high-impact rendering drivers for home healthcare devices. Home healthcare is a cost-effective alternative to expensive hospital stays, which is expected to boost the nebulizers market. Easy availability of compact nebulizers that are ideal for home use and technological innovations in nebulizers to reduce the sound created by them and to improve their functionality are increasing their adoption in home healthcare.

Regional Insights

North America commanded over 35.0% share of the nebulizer market in 2018 owing to growing respiratory disorders and efforts by the government such as favorable reimbursement scenario, rise in customer awareness, and well-established healthcare infrastructure. Furthermore, introduction of technologically advanced devices and favorable reimbursement scenario in this region are expected to fuel market growth in this region. However, Asia Pacific is expected to be the fastest growing market over the forecast period owing to large geriatric population, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, according to Japan’s Ministry of Health, Labor and Welfare, 2017, COPD is the seventh most common cause of death in the country.

A significant increase in the number of application areas, such as postoperative rooms, delivery rooms, and care units, of respiratory devices is expected to increase the demand for technologically advanced devices in the Europe. According to WHO data, about 2.9 million people in Europe are suffering from COPD; whereas, as per NCBI, approximately 43,000 people died due to asthma in Europe in 2017.

A large population base in Brazil is affected by pulmonary disorders, such as asthma and COPD, which require nebulizers for management.  Moreover, a study by Rehabilitation Center at Federal University in 2017, shows that in most Latin America countries, the prevalence of asthma varied from 2.6% in Guatemala to 33.1% in Peru.

Nebulizer Market Share Insights

The market for nebulizer is a matured market with major players such as Omron, Koninklijke Philips, PARI comprising of the major market share. However, the introduction of technologically advanced mesh nebulizers has created many opportunities for the companies such as Vectura Group, PARI Pharma and others. Many pharmaceutical companies are also using mesh nebulizers for drug development. For instance, as per the analysis of the U.S. and EU clinical trial databases, 2017, mesh nebulizers are more preferred for clinical trials sponsored by pharmaceutical companies over jet nebulizers.

The companies are currently working on technologically advanced products to differentiate their products form the other market players. For instance; in October 2018, Pari Pharma gets approval for its e-FLOW technology device LAMIRA, which is the only nebulizer system to deliver amikacin liposome inhalation suspension (ARIKAYCE).  Moreover, ARIKAYCE is used for the treatment of mycobacterium avium complex lung disease in adult patients. Furthermore, in Nov 2018, Koninklijke Philips launched InnoSpire Go portable nebulizer in U.S. The product is the smallest and lightest portable handheld nebulizer.

Report Scope

Segments covered in the report

This report forecasts revenue growth at global, regional, & country levels, and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global nebulizer market report on the basis of type, end-use, and region:

• Type Outlook (Revenue, USD Million, 2014 - 2026)

  • Jet

  • Mesh

    • Active

    • Passive

  • Ultrasonic

• End-use Outlook (Revenue, USD Million, 2014 - 2026)

  • Hospitals and Clinics

  • Emergency Centers

  • Home Healthcare

• Regional Outlook (Revenue, USD Million, 2014 - 2026)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • Malaysia

    • Philippines

    • Indonesia

    • Singapore

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa